Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

2.53USD
19 Sep 2017
Change (% chg)

-- (--)
Prev Close
$2.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
350,301
52-wk High
$5.01
52-wk Low
$2.20

Latest Key Developments (Source: Significant Developments)

Celldex Therapeutics Q2 loss per share $0.23
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Celldex Therapeutics Inc :Celldex reports second quarter 2017 results.Q2 loss per share $0.23.Q2 revenue $3.8 million versus $2.7 million.Q2 revenue view $1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Therapeutics Q2 loss per share $0.23
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Celldex Therapeutics Inc :Celldex reports second quarter 2017 results.Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million.Q2 loss per share $0.23.Q2 revenue view $1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Therapeutics promotes Sam Martin as CFO
Friday, 16 Jun 2017 08:01am EDT 

June 16 (Reuters) - Celldex Therapeutics Inc -:Celldex Therapeutics announces additions to the board of directors and senior management team.Celldex Therapeutics Inc - Sam Martin has been promoted to senior vice president and chief financial officer, effective July 1, 2017.Celldex Therapeutics Inc - Martin will assume responsibilities of Avery Catlin, who is retiring on June 30, 2017.  Full Article

Celldex reports Q1 loss per share $0.28
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Celldex Therapeutics Inc :Celldex reports first quarter 2017 results.Q1 loss per share $0.28.Q1 revenue $1.5 million versus $1.3 million.Q1 revenue view $923,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Q4 revenue $1.9 million versus $5.5 million
Tuesday, 14 Mar 2017 04:01pm EDT 

Celldex Therapeutics Inc : Celldex provides corporate update and reports full year 2016 results . Q4 loss per share $0.30 . Q4 revenue $1.9 million versus $5.5 million . Q4 revenue view $1.1 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S . Celldex therapeutics - cash, cash equivalents and marketable securities as of dec 31, 2016 were $189.8 million compared to $203.2 million as of sept 30, 2016 . Celldex therapeutics inc says chip catlin, senior vice president and chief financial officer, shared his intention to retire in june this year . Says sam martin, current vice president of finance will be promoted to cfo role concurrent with chip's departure . Celldex therapeutics inc- increase in qtrly revenue was primarily due to clinical trial collaboration with bristol-myers squibb and increase in grant revenue .Celldex therapeutics- cash,cash equivalents,marketable securities at dec 31,enough to meet estimated working capital,fund planned operations through 2018.  Full Article

Celldex Therapeutics files for offering of up to 18.4 mln shares of common stock
Thursday, 26 Jan 2017 04:29pm EST 

Celldex Therapeutics Inc :Files for offering of up to 18.4 million shares of common stock by the selling stockholders.  Full Article

Celldex reports second quarter 2016 results
Monday, 8 Aug 2016 04:01pm EDT 

Celldex Therapeutics Inc : Q2 revenue $1.4 million versus $2.7 million . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S . Celldex reports second quarter 2016 results . Q2 loss per share $0.32 .Q2 revenue view $850,000 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

* Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer